Dr. Reddy's Launches First Generic Bosulif in the U.S. for Leukemia Treatment

Key Facts

In a move reflecting the accelerating competition within the generic pharmaceutical market, Dr. Reddy's Laboratories has launched Bosutinib Tablets (400mg) in the United States. These tablets represent the first generic version of Pfizer's Bosulif, a medication used for the treatment of chronic myeloid leukemia. According to reports, this launch aims to provide cost-effective treatment alternatives while leveraging the company's first-to-market advantage for this specific generic molecule.

This expansion comes as global pharmaceutical firms face increasing pressure to lower costs, following a period where Pfizer's Bosulif maintained significant annual sales in the U.S. prior to patent expiration. Compared to its peers, Dr. Reddy's is strategically positioning itself to capture market share in the high-margin oncology sector. Per market data, the entry of first-to-market generics typically leads to price reductions ranging from 20% to 80% compared to branded counterparts, impacting the revenue streams of major players like Pfizer.